Lucence Diagnostics
Singapore, Singapore· Est.
Singapore‑born precision‑diagnostics firm delivering AI‑enhanced liquid‑biopsy and early‑cancer detection tests.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
Singapore‑born precision‑diagnostics firm delivering AI‑enhanced liquid‑biopsy and early‑cancer detection tests.
Oncology
Technology Platform
Proprietary AmpliMARK™ technology combines ultra‑sensitive NGS with molecular barcoding to detect ctDNA and ctRNA, enhanced by AI for rapid, high‑resolution tumor profiling.
Opportunities
Expansion of MCED and multi‑disease panels across emerging Asian markets and deeper integration of AI‑driven analytics to capture longitudinal monitoring services.
Risk Factors
Regulatory and reimbursement uncertainties, intense competition from larger liquid‑biopsy firms, and reliance on sustained partner collaborations for market access.
Competitive Landscape
Key competitors include Guardant Health, Foundation Medicine, and Roche; Lucence differentiates through combined ctDNA/ctRNA detection, AmpliMARK™ sensitivity, and AI‑enhanced reporting.